Business and Finance

Sales volume handled by primary wholesaler/distributors seems to be declining

HFAP builds out from its hospital-accreditation business

Already-built Las Colinas facility will be the global headquarters in April 2019

Most pharmacists want more time to counsel patients; most are concerned with drug reimbursement issues

Billions of dollars are at stake with analyzing and optimizing GTN decisions

PBM squares the circle by offering a lower drug price—where some payers wouldn’t want it

Current McKesson president, Brian Tyler, will take over in April 2019

Biologics, RxCrossroads units will retain their identity

JC Scott takes over as the PBM business undergoes a transformation

Known as the “King of Cold Chain,” Bishara looks both back and ahead at progress in upgrading pharma’s logistics practices

Will the “United States-Mexico Trade Agreement” replace Nafta?

CVS and Express Scripts open more of the curtain around rebates; formulary exclusions grow

HDA issues a report detailing recalls and returns

Alliance for Regenerative Medicine tries to rationalize how payers address economic value

FDA working group’s effort is part of a larger move to realign drug pricing policies

PBMs, wholesalers and insurers lose over $20 billion in stock value on day of announcement

Will a combination of better diagnosis resources and cost cutting lead to better patient outcomes?

Data are down for 2016-7, but still relatively high compared to prior years; UPDATED

Questions raised over how prescription dosages translate into bulk consumption; IQVIA ‘stand(s) behind our data methodologies’

Eagerly anticipated address avoids major policy changes while chipping away at well-recognized pricing disincentives

With new cellular and genetic therapies, the reimbursement process will need to evolve

Purchases totaled $19.3 billion, up 19% over 2016, say Drug Channels' Adam Fein

Move comes as drug pricing policies get heightened attention in Washington

Company celebrates its growth at annual industry event

While nominal spending was up 1.4%, actual net spending was only 0.6% greater than 2016

Projected growth rates for outsourced work range from 12 to 17%

So-called ‘off the shelf’ CAR-T treatments could change the field just as first products enter commercialization

Existing ‘pay for performance’ models do not scale up well yet

Forecast is for 3-6% CAGR through 2022